NEWS & EVENTS
SubjectWell news
Stay informed and updated on SubjectWell news and our impact on patient recruitment and commercial execution.
Learn what an ideal patient journey could look like in a trial when site and patient support are optimized.
A real-world evidence study published in JMIR reports results on a survey of 3,546 women in Germany, Austria, and Poland showing high pain burden but low diagnosis rates; targeted online campaigns demonstrated strong ability to engage affected, often undiagnosed, populations
Steve will will drive innovation and AI strategy, while strengthening security and compliance to advance SubjectWell’s Patient Experience Platform.
Learn how digital, design, data, and dedicated support can turn hard-to-reach patients into engaged clinical trial participants.
SubjectWell welcomes veteran healthcare finance leader Karl Stubelis as CFO to help scale global growth and accelerate patient recruitment.
SubjectWell CEO Fred Martin speaks with the AI journal on AI’s transformative potential in clinical trial recruitment—offering faster, more precise, and more inclusive patient identification—while also addressing the industry's deep hesitations around patient safety, data privacy, explainability, and regulatory clarity.
SubjectWell CEO Fred Martin speaks with PharmaTech News on why many studies struggle to enroll the required number of eligible participants on schedule, and what that means for trial success.
Join experts from Subjectwell and Veristat in this virtual roundtable as they discuss proven approaches for navigating the complexities of modern clinical trials.
SubjectWell SVP of Marketing, Suzanne Harris, speaks with MedCity News on patient-centric practices that benefit the entire healthcare ecosystem.
It’s time to transform patient recruitment
The clinical trial landscape has changed dramatically. Protocols are more complex, patient needs have evolved, and regulatory standards are ever-changing. Globalization has made finding patients even more challenging. Yet, patient recruitment strategies have remained stagnant, leading to an 80% clinical trial failure rate and $40 billion in unrecoverable losses. (BioPharma Dive. January 29, 2019.)
Their tailored approach helped us meet our recruitment target ahead of schedule. Highly recommend!
Name
Job Description
Get started with SubjectWell
Patient-centricity is paramount. Breakthroughs are in demand. Let’s change patient recruitment and commercial development together.
